Foghorn Therapeutics Inc. [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Assets
Current assets:
Cash and cash equivalents	57.7	50.6	52.2	87.6	61.2	213.6	101.1	57.8
Marketable securities	226.6	265.3	293.6	285.9	333.5	211.1	53.2	63.0
Prepaid expenses and other current assets	6.2	4.7	5.6	4.2	5.3	5.1	5.3	3.1
Total current assets	290.5	320.7	351.4	377.8	400.1	429.8	459.6	124.0
Property and equipment, net	14.6	15.2	15.3	15.9	16.5		17.6
Restricted cash	1.7	1.7	1.7	0.0	1.7		1.7
Other assets	1.2	2.4	2.4	2.4	2.4	2.4	2.4	2.4
Operating lease right-of-use assets	31.6	32.9	34.1	36.2	36.3		38.5
Total assets	339.6	372.9	404.9	433.9	456.9	488.3	519.8	186.1

Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	6.9	7.3	5.4	5.3	3.6	5.1	3.8	3.8
Accrued expenses and other current liabilities	8.1	8.8	11.0	10.1	8.1	7.0	9.6	7.2
Operating lease liabilities	7.7	6.3	6.0	6.7	5.7		7.0
Deferred revenue	33.9	33.3	32.8	33.2	30.6		28.3
Total current liabilities	56.6	55.8	55.2	55.2	48.0	48.2	48.7	19.3
Operating lease liabilities, net of current portion	40.3	43.5	45.5	46.5	49.1		51.3
Deferred revenue, net of current portion	292.0	298.2	304.0	307.8	312.1		322.7
Other liabilities			0.0	0.1	0.1	0.1	0.1	0.2
Total liabilities	388.9	397.5	404.8	409.6	409.3	415.9	422.9	105.1

Commitments and contingencies (Note 10)
Stockholders’ equity (deficit):
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Additional paid-in capital	386.5	381.9	377.2	373.4	369.3	364.8	361.1	316.1
Accumulated other comprehensive loss	-2.7	-2.9	-4.0	-4.9	-3.2	-1.2	0.0	0.0
Accumulated deficit	-433.1	-403.6	-373.1	-344.3	-318.5	-291.2	-264.3	-235.1
Total stockholders’ equity (deficit)	-49.4	-24.6	0.1	24.3	47.6	72.4	96.9	81.0
Total liabilities and stockholders’ equity (deficit)	339.6	372.9	404.9	433.9	456.9	488.3	519.8	186.1